About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

oh for gods sakes..

are you seriously this blind..

YES YES YES

(AP) - In a Dec. 11 story about licensing deals in the biotechnology sector, The Associated Press erroneously named the employer of analyst Eric Ende. He works for Merrill Lynch, not Bank of America. A corrected version of the story appears below.

NEW YORK (AP) -- Last week's licensing deal between Roche Holding AG and Halozyme Therapeutics Inc. potentially worth as much as $581 million over the next 10 years marked another highlight for the biotechnology sector, as analysts predict licensing costs will get steeper.

Related newsJapanese Stocks Fall; Dollar DownInvestors Seek Signs of Robust SpendingMore Jobs in Nov., Unemployment Up Too
Licensing deals between pharmaceutical and biotechnology companies is the norm for the industry, giving development stage companies the money to continue developing products, while larger companies get a chance to bolster their product pipelines.

But with more large companies facing pipeline holes, biotech companies are seeing more money being thrown their way for innovative products, and the deals could lead to future acquisitions.

"That's going to continue to heat up and pick up," said Jason Napadano, senior biotechnology analyst at Zach's Investment Research. "The reason it's happening is that you have these large pharmaceutical companies with an unprecedented number of products going off patent."

That could amount to billions of dollars in losses for some of the major pharmaceutical companies.

The deal last week between Halozyme and Roche calls for the use of Halozyme's drug delivery technology in products being developed by Roche.

Some of the more standard licensing agreements entail the smaller biotechnology company developing the drug with payments from its larger partner, then splitting, in some form, the profits when it hits the market.

Bank of America analyst Eric Ende said in a November report that smaller biotech companies have been seeing higher deal prices as they seek to gain more control over their products. And big pharma has been willing to pay to fill lagging pipelines. The higher licensing prices are partially leading to more expensive buyout deals.

In October, Merck & Co. said it would buy small biotechnology outfit Sirna Therapeutics Inc. for $1.1 billion. Abbott Laboratories is in the process of buying Kos Pharmaceuticals for $3.7 billion.

"Big pharma could start knocking on the door of biotech with market caps of $5 billion," said Morningstar analyst Karen Andersen.

"If you're a pharmaceutical company and you want these products and need these products, biotech can continue to demand these types of big prices," Zack's Napadano said.

By most estimates, the market for licensing deals and pricier acquisitions will continue into 2007. News last week that Pfizer Inc. ended a late-stage program on its experimental heart drug highlighted the company's pipeline problems, with many analysts predicting it will acquire another company, possibly within the next year.

its your last chance to top up now!!!

I can't find the connection only that survivin is mentioned in the pdf file in the header, having said that if mike says there is one, there may be.

Finds known targets (e.g. aurora, survivin, PKC)

http://www.eirx.com/eirx_heading_images/Yokohama2005.pdf

Also here.

As little as 5 years ago cancer was still thought of largely in terms of a proliferative disease. In contrast, EiRx has built its discovery model around what has now become established dogma; namely that cancer cells critically require a block on the induction of apoptosis. Experiments have shown that proliferative stimuli alone, such as overexpression of the oncogene cMyc, rapidly trigger apoptosis and elimination of the cell. In this context, induction of apoptosis can be seen as a safety mechanism. Blockade of apoptosis can occur through dysregulation of apoptosis effectors such as p53 or from an increase in a survival signals, such as upregulation of discrete genes (e.g. survivin and bcl2) or from the up regulation of an entire survival pathway (e.g. PI3K/AKT).

The charts below illustrates example results from these assays. Survivin and aurora, both of which were identified using ALIBI, represent control genes. Extensive data generated for all kinase, GPCR and other enzyme targets demonstrates direct functional modulation of apoptosis and cancer cell death, from both long term clonagenicity and molecular apoptosis assays. Induction of apoptosis and cell death for many targets compares well with siRNA specific to survivin and aurora controls

http://www.billamag.net/focus-text-main-quoted.asp?FocusTextID=33

there is, its been confirmed by phone by mike if you go over to the dark side

I stand by my post 732.

PH - Your post 735 in response has again NOTHING TO DO WITH EIRx.

Driver - I'm not sure what your handle is on this little tete-a-tete. I'm not denying that EIRx have patents involving the use of Survivin, I'm just questioning PH's implication of a tie-up with Eli Lilly (something that he still refuses to provide evidence for).

I just checked mikes post; he didnt say there was a connection he said, Survivin does connect back to ERX which is a different thing.

But PH never lets the facts spoil a good story. ;-)

LOL

he rang the company according to him on the darkside

latest over-hyped ramped dog

zscrooge

We are trying not to ramp ERX on this thread, only after the facts. The right deal or some milestone payments from the companies below will see ERX a multi bagger with out any ramping.


4 licensed to OSI Pharmaceuticals (oncology)
- compound library screening approach
- up to $18.8 M in upfront and milestones


5 in collaborative drug discovery with Sareum (all fields)
- structure-based rational drug design strategy
- develop to Phase I/II

Can I smell something?

I smell news..

Yes pothead, have been over and had a read ! we will see :)

I smell news..

I smell Bull.

I smell news..

Luckypicker - 12 Dec'06 - 12:07 - 14953 of 14956


"john"
12/12/2006 11:53
To
XXX

Subject
Re: Shareholder Question





Hi
As CEO as just returned from the US completing statements
J
------------------
Sent with Instant Email from T-Mobile

-----Original Message-----
From: XXXX
Date: Tue, 12 Dec 2006 11:51:22
To:"John K Pool"
Subject: Re: Shareholder Question

Dear John

why no RNS??






Presenting it like this would've helped - nice find though.- I believe this is worthy of RNS

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
ABOUT LY2181308 AND SURVIVIN
LY2181308 targets survivin, a molecule that supports the survival of
cells that would normally die through programmed cell death or apoptosis.
Survivin helps in the abnormal growth of cancer cells, and is abundant in
many types of cancers, including colon, brain, lung, skin and others, but
nearly nonexistent in normal cells and tissues.

------------------------------------------------------------------------------------------------------------
-

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

------------------------------------------------------------------------------------------------------------
-
CARLSBAD, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Eli Lilly and
Company (NYSE: LLY) highlighted two antisense oligonucleotide (ASO) drugs
in its "Update to Wall Street on Strategic Priorities and Pipeline
Progress" on Thursday. Advances with both survivin ASO (LY2181308) and
eIF-4E ASO (LY2275796) drugs were singled out among Select Early- to
Mid-Stage Pipeline Developments. Based on promising activity in early
studies, Lilly said that it is initiating Phase 2 trials for survivin ASO
in a broad range of cancers including liver cancer, prostate cancer, acute
myelogenous leukemia, ovarian cancer and non-small cell lung cancer; the
first of these trials is planned to begin this month. Lilly also said that
the Phase 1 development program for eIF-4E ASO is progressing well.
"We are pleased that Lilly includes our collaboration drugs among its
selected strategic priorities," commented C. Frank Bennett, Ph.D., Isis'
Senior Vice President of Research. "These drugs resulted from our
productive collaboration and Lilly's broad investment in antisense
technologies. We continue to work together and hope that additional drugs
will arise from our collective efforts. Lilly's progress with these
anti-cancer drugs emphasizes the broad therapeutic potential of Isis'
platform antisense technologies, and underscores our strategy of working
with partners to expand the scope of our development pipeline.





Kind regards